Overview
SS-31, also known as elamipretide, is a synthetic mitochondria-targeting tetrapeptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2) that has generated significant scientific interest for its potential to address cellular energy dysfunction across multiple health conditions. Unlike conventional medications that work systemically, SS-31 selectively accumulates in the inner mitochondrial membrane, where it binds to cardiolipin—a phospholipid unique to this cellular compartment.
The compound is currently investigational, with no FDA approval to date, but has advanced through Phase I and Phase II clinical trials for conditions including heart failure, kidney injury, mitochondrial myopathy, and age-related decline. The peptide is administered by injection (intravenous or subcutaneous) and costs between $80–$400 per month depending on dosing and source.
This article synthesizes current evidence across multiple health domains, providing evidence tiers, specific study findings, dosing information, and safety considerations to help readers understand both the potential and limitations of this emerging compound.
How SS-31 Works: Mechanism of Action
SS-31 functions through a cardiolipin-protective mechanism rather than as a conventional antioxidant. Here's how it works at the molecular level:
Cardiolipin Stabilization and Electron Transport Chain Preservation
SS-31 binds with high affinity to cardiolipin, a specialized phospholipid concentrated in the inner mitochondrial membrane. This binding stabilizes the interaction between cardiolipin and cytochrome c, a critical protein in the electron transport chain responsible for ATP synthesis. By preserving this interaction, SS-31 maintains the structural integrity of the electron transport chain and supports efficient oxidative phosphorylation—the process cells use to generate energy.
Prevention of Cardiolipin Peroxidation
As mitochondria age or encounter stress, cardiolipin becomes oxidized (peroxidized), which disrupts its function. SS-31 prevents this oxidation, reducing the generation of reactive oxygen species (ROS) within the mitochondria. This is particularly important because elevated mitochondrial ROS triggers a cascade that leads to the release of cytochrome c and pro-apoptotic factors into the cytoplasm, ultimately triggering cell death.
Restoration of Mitochondrial Membrane Potential and Structure
By protecting cardiolipin, SS-31 helps restore the mitochondrial membrane potential—the electrical gradient essential for ATP production. The compound also improves cristae morphology (the folded structure of the inner mitochondrial membrane), allowing for better packing of the electron transport chain components and more efficient energy production.
Mechanism Does Not Rely on Free Radical Scavenging
It's important to note that SS-31 does not function as a direct free radical scavenger. Instead, its benefits arise from stabilizing mitochondrial architecture and function, which secondarily reduces ROS generation and oxidative stress. This distinction is significant because it suggests SS-31 may have broader cellular benefits than conventional antioxidants.
Evidence by Health Goal
Evidence for SS-31's efficacy varies considerably across different health domains. Each section below includes the evidence tier (ranging from Tier 1 for no human evidence, to Tier 3 for probable human efficacy) and specific study findings.
Fat Loss
Evidence Tier: 2 — Mechanistic promise with limited human evidence.
SS-31 shows consistent benefits for mitochondrial function, and animal studies suggest modest effects on body composition, but robust human evidence for fat loss is absent. No human randomized controlled trials (RCTs) have evaluated fat loss as a primary outcome.
Key Findings:
- In a mouse model of high-fat diet-induced kidney disease, SS-31 preserved mitochondrial structure and kidney function over 28 weeks but had no effect on weight gain, insulin resistance, or glucose metabolism (n=6 per group).
- In cancer cachexia mice, SS-31 partially counteracted body and muscle weight loss and prevented reduction of glycolytic muscle fiber area, though benefits were transient (observed at day 21 but lost by day 28 in end-stage disease).
Muscle Growth and Strength
Evidence Tier: 2 — Promise for muscle-related conditions in disease states; limited evidence for healthy muscle hypertrophy.
SS-31 shows meaningful benefits in disease-specific muscle conditions (Barth syndrome, dexamethasone-induced muscle atrophy), but robust evidence for muscle hypertrophy in healthy individuals is lacking.
Key Findings:
- In Barth syndrome patients (n=12), daily elamipretide 40 mg produced a cumulative 96.1-meter improvement in the 6-minute walk test (6MWT) over 168 weeks (P=0.003), indicating sustained functional muscle benefit.
- In an in vitro model of dexamethasone-induced muscle cell aging, SS-31-loaded microspheres significantly alleviated mitochondrial dysfunction and senescent phenotypes by activating the AMPK-SIRT1-PGC1α pathway, a key regulator of mitochondrial biogenesis.
Injury Recovery
Evidence Tier: 3 — Probable human efficacy based on small pilot trials.
SS-31 demonstrates mitochondrial protection during ischemia-reperfusion injury (when blood flow is restored after being blocked) in human trials, though evidence is limited to small studies without independent replication.
Key Findings:
- In a Phase 2a RCT of renovascular hypertension (n=14), elamipretide reduced post-operative tissue hypoxia to -6% compared to +47% in placebo (P<0.05) and increased renal blood flow by 30% (262±115 mL/min) in the treated group at 3 months.
- In dogs with heart failure (n=14), chronic elamipretide improved ejection fraction from 30±2% to 36±2% (P<0.05) and decreased NT-proBNP (a marker of heart stress) by 774±85 pg/mL, while the control group showed an increase of 88±120 pg/mL.
Joint Health
Evidence Tier: 2 — Plausible efficacy from preclinical models; no human evidence.
SS-31 shows protective effects in cartilage and joint injury models, but human efficacy trials are absent.
Key Findings:
- In bovine cartilage explants subjected to impact injury, SS-31 (1 μM) preserved chondrocyte (cartilage cell) viability and prevented impact-induced apoptosis, cell membrane damage, and cartilage matrix degradation over 7 days of culture.
- In equine (horse) joint injury models, SS-31 reduced mitochondrial DNA release. In naturally occurring post-traumatic osteoarthritis cases, synovial fluid mitochondrial DNA concentration showed a strong positive correlation with cartilage damage (r = 0.80, P = 0.0001), and this elevation was reduced by SS-31 treatment.
Anti-Inflammation
Evidence Tier: 2 — Consistent anti-inflammatory effects in animal models and cell culture; human efficacy unproven.
SS-31 demonstrates anti-inflammatory mechanisms in laboratory studies but lacks human RCTs specifically measuring inflammatory outcomes.
Key Findings:
- In human cardiomyocytes derived from patients with myocarditis, SS-31 inhibited NLRP3 inflammasome activation and reduced pro-inflammatory cytokine levels, attenuating drug-induced cardiotoxicity.
- In hepatocytes treated with lipopolysaccharide (LPS), SS-31 promoted autophagy (cellular cleanup) by upregulating ATG5 expression and inhibited inflammatory cytokine production.
Cognition
Evidence Tier: 2 — Consistent neuroprotection in animal models; no human RCTs.
SS-31 shows promise for preserving cognitive function in injury and neurodegeneration models, but human efficacy trials are absent.
Key Findings:
- In developing rats exposed to isoflurane anesthesia, SS-31 pretreatment prevented cognitive deficits measured at postnatal days 40 and 60, accompanied by reduced ROS accumulation and normalized mitochondrial morphology in the hippocampus.
- In rats with mild traumatic brain injury, SS-31 reversed increased mitochondrial and cytoplasmic superoxide production in cerebral blood vessels, normalizing levels to control animals.
Mood and Stress
Evidence Tier: 1 — No human studies; limited mechanistic animal data.
SS-31 has not been investigated for mood or stress in humans. All evidence comes from animal models and mechanistic studies related to different conditions.
Longevity
Evidence Tier: 2 — Mechanistic benefits in aging models; no human longevity data.
SS-31 shows consistent improvements in mitochondrial function and cellular markers of aging, but direct evidence for lifespan extension in humans is absent.
Key Findings:
- In aged human bone marrow stem cells (in vitro), SS-31 increased ATP production by 35%, reduced ROS by 40%, and produced a 2.8-fold increase in osteogenic (bone-forming) differentiation markers.
- In murine cancer cachexia models, SS-31 prevented reduction of glycolytic muscle fiber area and rescued intracellular ATP levels, though benefits were transient (21 days) before the disease reached a refractory state.
Immune Support
Evidence Tier: 2 — Mechanistic benefits in laboratory models; no human immune function trials.
SS-31 demonstrates immune-modulating effects in cell culture and animal models, primarily through mitochondrial protection and inflammatory marker reduction. No human RCTs specifically assessing immune function have been conducted.
Key Findings:
- In an in vitro sepsis model (LPS-treated THP-1 cells), SS-31 reduced TNF-α production by approximately 42% (529.29 vs 915.91 pg/mL, p<0.05).
- In spinal cord injury-induced lung injury models in mice, SS-31 reduced total macrophages and pro-inflammatory M1 macrophages, decreased neutrophil infiltration, and inhibited NLRP3 inflammasome activation.
Energy and Exercise Capacity
Evidence Tier: 3 — Probable human efficacy based on clinical trial data in mitochondrial disease patients.
SS-31 demonstrates improvements in exercise capacity and fatigue in patients with mitochondrial myopathy, though results are mixed across different disease types and dosing protocols.
Key Findings:
- In Barth syndrome patients, a 96.1-meter cumulative improvement in 6MWT distance over 168 weeks was observed during open-label extension with elamipretide (n=10, sustained benefit).
- In primary mitochondrial myopathy with nDNA replisome variants, elamipretide produced a 25.2 ± 8.7-meter improvement on 6MWT versus 2.0 ± 8.6 meters with placebo, trending toward statistical significance.
- In primary mitochondrial myopathy, the highest-dose elamipretide (0.25 mg/kg/h IV) increased 6MWT distance by 64.5 meters versus 20.4 meters with placebo at day 5 (p=0.053, n=36, with a dose-dependent trend p=0.014).
Skin and Hair Health
Evidence Tier: 1 — No human studies; preliminary cell culture data only.
SS-31 has not been evaluated in human skin or hair health studies. One in vitro study suggests potential UV protection benefits.
Key Findings:
- SS-31 incorporated into exosomes (Exo-SS31) suppressed ROS production in human dermal fibroblasts exposed to UV radiation more effectively than SS-31 alone and reduced expression of collagen-degrading enzymes (MMP1 and MMP3).
Gut Health
Evidence Tier: 2 — Mechanistic promise through mitochondrial targeting; no human efficacy trials.
SS-31 is theoretically relevant for gut health through reduction of mitochondrial oxidative stress, but evidence is limited to mechanistic discussions and proof-of-concept delivery systems.
Key Findings:
- SS-31 has been incorporated into regulatory T cell-derived exosomes decorated with selenium for theoretical targeted delivery to inflamed intestinal lesions in inflammatory bowel disease, though this remains untested in animal or human IBD studies.
Heart Health
Evidence Tier: 3 — Promising mitochondrial effects with mixed human trial results.
SS-31 shows theoretically sound benefits for heart failure through mitochondrial protection, but several large human RCTs have failed to meet primary endpoints, suggesting efficacy is probable but not conclusively proven.
Key Findings:
- A single 4-hour infusion of the highest-dose elamipretide (0.25 mg·kg⁻¹·h⁻¹) reduced left ventricular end-systolic volume (LVESV) by 14 mL (p=0.005) versus placebo in an 8-patient cohort (n=24 total).
- In a 28-day daily subcutaneous elamipretide trial (PROGRESS-HF), both the 4 mg and 40 mg doses did not significantly improve LVESV or left ventricular ejection fraction (LVEF) compared to placebo in 71 patients.
Liver Health
Evidence Tier: 2 — Consistent hepatoprotective effects in animal models; no human RCTs.
SS-31 demonstrates liver-protective effects in animal models through mitochondrial-targeted antioxidant mechanisms, but human efficacy remains unproven.
Key Findings:
- In rats with severe burns plus delayed resuscitation, SS-31 prevented hepatic injury by suppressing the mtDNA/STING pathway in Kupffer cells (liver immune cells) and reducing oxidative stress.
- In TGF-β1-activated hepatic stellate cells, SS-31 decreased mitochondrial ROS, restored ATP levels, reduced fibrotic marker expression (COL1A1, α-SMA), and suppressed NLRP3 inflammasome activation. In CCl4-induced liver fibrosis mice, SS-31 reduced collagen deposition.
Hormonal Balance
Evidence Tier: 2 — Mechanistic promise in animal models; no human RCTs.
SS-31 shows potential for hormonal health through mitochondrial protection, but evidence remains limited to animal and cell studies.
Key Findings:
- In adolescent female rats co-exposed to polystyrene nanoplastics and cadmium, SS-31 reversed ovarian toxicity, reduced atretic (degenerative) follicle numbers, and restored endocrine function by inhibiting ferroptosis via the SIRT3-SOD2/Gpx4 pathway.
- In mouse ovarian tissue cryopreservation, 100 μmol/L SS-31 significantly improved follicle quality and oocyte maturation rate in vitro, increased mitochondrial DNA copy number and ATP content, and upregulated mitochondrial metabolism genes (SIRT1, PGC-1α, PPAR-α, TFAM).
Athletic Performance
Evidence Tier: 3 — Probable efficacy for exercise tolerance in mitochondrial myopathy patients.
SS-31 shows consistent improvements in exercise endurance in animal studies and modest benefits in human trials of patients with mitochondrial myopathy, though results vary by disease type and dosing.
Key Findings:
- In humans with primary mitochondrial myopathy, the highest-dose elamipretide (0.25 mg/kg/h IV) increased 6MWT distance by 64.5 meters versus 20.4 meters with placebo at day 5 (p=0.053, n=36, dose-dependent trend p=0.014).
- In a 4-week subcutaneous elamipretide trial (40 mg/day) in mitochondrial myopathy patients (n=30), 6MWT improved by 19.8 meters versus placebo (p=0.0833, not statistically significant), but fatigue scores improved significantly (p=0.0006–0.0421).
Dosing Protocols
SS-31 is administered by injection only. Recommended dosing ranges are:
Standard Dosing:
- 0.1–0.5 mg/kg or fixed 4–40 mg administered once daily
- Route: Intravenous infusion or subcutaneous injection
- Clinical trial dosing: Doses tested have ranged from 4 mg to 40 mg subcutaneously, or 0.25 mg/kg/h intravenously for infusion protocols
Important Considerations:
- Dosing should be individualized based on body weight, route of administration, and clinical indication
- SS-31 is an investigational compound; dosing protocols vary across clinical trials
- Subcutaneous administration appears better tolerated than intravenous infusion in some studies
- Long-term optimal dosing schedules beyond 28 days remain undefined
Side Effects and Safety Profile
Common Side Effects (Incidence 30–40% in trials)
Injection Site Reactions: